Skip to product information
1 of 1

BT Lab

SKU:BT-MCA0330

Cdk4 Monoclonal Antibody

Cdk4 Monoclonal Antibody

Regular price $300.00 USD
Regular price Sale price $300.00 USD
Sale Sold out
Shipping calculated at checkout.
Size
Host
Ab type

The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported.

Introducing the CDK4 Monoclonal Antibody, a cutting-edge product designed to revolutionize the field of cancer research and treatment. This highly specialized antibody is meticulously engineered to target and inhibit the cyclin-dependent kinase 4 (CDK4) protein, a key player in cell cycle regulation and tumor progression.

With its exceptional specificity and affinity, the CDK4 Monoclonal Antibody offers unparalleled precision in selectively binding to CDK4, thereby impeding its enzymatic activity. By doing so, it effectively disrupts the cell cycle progression, halting the uncontrolled proliferation of cancer cells and ultimately suppressing tumor growth.

The CDK4 Monoclonal Antibody boasts an array of remarkable features that set it apart from conventional therapeutic options. Its monoclonal nature ensures consistent and reproducible results, guaranteeing reliability in experimental settings. Furthermore, its exceptional purity and low endotoxin levels minimize the risk of unwanted side effects, making it an ideal candidate for clinical applications.

This groundbreaking product has undergone rigorous testing and validation, demonstrating remarkable efficacy in preclinical studies. Its potential to enhance the efficacy of existing cancer therapies and overcome drug resistance has garnered significant attention from the scientific community.

The CDK4 Monoclonal Antibody is supplied in a convenient and user-friendly format, allowing for easy integration into various research and clinical protocols. Its long shelf life and stability ensure optimal performance and longevity, making it a cost-effective solution for laboratories and healthcare facilities alike.

In summary, the CDK4 Monoclonal Antibody represents a game-changing advancement in cancer research and treatment. With its unrivaled specificity, reliability, and potential therapeutic benefits, it holds immense promise in combating various malignancies. Embrace the future of cancer therapy with the CDK4 Monoclonal Antibody and unlock new possibilities in the fight against cancer.

View full details